UTHR – United Therapeutics Corporation
Float Short %
6.17
Margin Of Safety %
-11
Put/Call OI Ratio
1.1
EPS Next Q Diff
0.02
EPS Last/This Y
0.04
EPS This/Next Y
1.12
Price
404.98
Target Price
480.09
Analyst Recom
1.62
Performance Q
41.55
Relative Volume
0.9
Beta
0.62
Ticker: UTHR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | UTHR | 313.26 | 0.81 | 3.55 | 47280 |
| 2025-08-18 | UTHR | 313.35 | 1.03 | 3.33 | 39475 |
| 2025-08-19 | UTHR | 313.33 | 1.03 | 1.98 | 39687 |
| 2025-08-20 | UTHR | 306.35 | 1.04 | 0.51 | 39904 |
| 2025-08-21 | UTHR | 310.62 | 1.01 | 0.17 | 40454 |
| 2025-08-22 | UTHR | 312.53 | 1.02 | 0.94 | 40490 |
| 2025-08-25 | UTHR | 305.48 | 1.01 | 78.90 | 40792 |
| 2025-08-26 | UTHR | 309.25 | 1.30 | 59.84 | 46739 |
| 2025-08-27 | UTHR | 305.19 | 1.53 | 3.91 | 51502 |
| 2025-08-28 | UTHR | 307.27 | 1.56 | 2.10 | 52719 |
| 2025-08-29 | UTHR | 304.8 | 1.82 | 0.11 | 56542 |
| 2025-09-02 | UTHR | 404.55 | 1.74 | 6.34 | 57521 |
| 2025-09-03 | UTHR | 392.12 | 1.54 | 0.62 | 53569 |
| 2025-09-04 | UTHR | 380.41 | 1.33 | 0.52 | 62900 |
| 2025-09-05 | UTHR | 400.66 | 1.27 | 0.44 | 69682 |
| 2025-09-08 | UTHR | 394.68 | 1.15 | 1.55 | 77149 |
| 2025-09-09 | UTHR | 403.84 | 1.13 | 0.47 | 79116 |
| 2025-09-10 | UTHR | 397.31 | 1.11 | 1.11 | 80649 |
| 2025-09-11 | UTHR | 403.84 | 1.11 | 0.47 | 81785 |
| 2025-09-12 | UTHR | 405.1 | 1.10 | 1.20 | 82922 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | UTHR | 313.09 | 9.9 | 52.6 | 26.95 |
| 2025-08-18 | UTHR | 314.29 | 9.9 | 53.4 | 26.95 |
| 2025-08-19 | UTHR | 313.22 | 9.9 | 39.3 | 26.95 |
| 2025-08-20 | UTHR | 306.41 | 9.9 | -1.8 | 26.95 |
| 2025-08-21 | UTHR | 310.67 | 10.2 | 75.3 | 26.59 |
| 2025-08-22 | UTHR | 312.20 | 10.2 | 56.2 | 26.59 |
| 2025-08-25 | UTHR | 305.18 | 10.2 | -3.8 | 26.59 |
| 2025-08-26 | UTHR | 309.22 | 10.2 | 73.0 | 26.59 |
| 2025-08-27 | UTHR | 305.20 | 10.2 | 17.0 | 26.59 |
| 2025-08-28 | UTHR | 307.24 | 10.2 | 58.9 | 26.59 |
| 2025-08-29 | UTHR | 304.99 | 10.2 | 29.4 | 26.59 |
| 2025-09-02 | UTHR | 404.54 | 10.2 | 762.4 | 26.59 |
| 2025-09-03 | UTHR | 391.94 | 10.2 | 11.6 | 26.59 |
| 2025-09-04 | UTHR | 380.44 | 10.2 | 19.2 | 26.59 |
| 2025-09-05 | UTHR | 400.52 | 10.2 | 188.8 | 26.59 |
| 2025-09-08 | UTHR | 394.62 | 10.2 | 47.0 | 26.59 |
| 2025-09-09 | UTHR | 403.56 | 4.0 | 125.0 | 26.48 |
| 2025-09-10 | UTHR | 396.40 | 4.0 | 39.5 | 26.48 |
| 2025-09-11 | UTHR | 404.84 | 4.0 | 121.7 | 26.48 |
| 2025-09-12 | UTHR | 404.98 | 4.0 | 78.4 | 26.48 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | UTHR | -15.31 | -0.70 | 3.56 |
| 2025-08-18 | UTHR | -15.31 | -2.26 | 3.56 |
| 2025-08-19 | UTHR | -15.31 | -2.26 | 3.59 |
| 2025-08-20 | UTHR | -11.75 | -2.26 | 3.59 |
| 2025-08-21 | UTHR | -11.75 | -2.26 | 3.59 |
| 2025-08-22 | UTHR | -12.32 | -2.26 | 3.59 |
| 2025-08-25 | UTHR | -12.32 | -2.02 | 3.59 |
| 2025-08-26 | UTHR | -11.80 | -2.02 | 3.59 |
| 2025-08-27 | UTHR | -11.80 | -2.02 | 6.53 |
| 2025-08-28 | UTHR | -11.80 | -2.02 | 6.53 |
| 2025-08-29 | UTHR | -11.80 | -2.02 | 6.53 |
| 2025-09-02 | UTHR | -11.96 | -1.89 | 6.53 |
| 2025-09-03 | UTHR | -11.96 | -1.89 | 6.53 |
| 2025-09-04 | UTHR | -12.22 | -1.89 | 6.53 |
| 2025-09-05 | UTHR | -12.29 | -1.89 | 6.53 |
| 2025-09-08 | UTHR | -12.29 | -2.13 | 6.53 |
| 2025-09-09 | UTHR | -12.29 | -2.13 | 6.53 |
| 2025-09-10 | UTHR | -13.80 | -2.13 | 6.53 |
| 2025-09-11 | UTHR | -13.80 | -2.13 | 6.17 |
| 2025-09-12 | UTHR | -14.10 | -2.13 | 6.17 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
6.41
Avg. EPS Est. Current Quarter
6.94
Avg. EPS Est. Next Quarter
6.43
Insider Transactions
-14.1
Institutional Transactions
-2.13
Beta
0.62
Average Sales Estimate Current Quarter
814
Average Sales Estimate Next Quarter
803
Fair Value
362.38
Quality Score
100
Growth Score
97
Sentiment Score
80
Actual DrawDown %
7.3
Max Drawdown 5-Year %
-33
Target Price
480.09
P/E
15.81
Forward P/E
13.92
PEG
2.86
P/S
5.95
P/B
2.55
P/Free Cash Flow
17.15
EPS
25.61
Average EPS Est. Cur. Y
26.48
EPS Next Y. (Est.)
27.6
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
40.36
Relative Volume
0.9
Return on Equity vs Sector %
-7.6
Return on Equity vs Industry %
9.5
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.48
EBIT Estimation
78.4
United Therapeutics CorporationSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1305
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
stock quote shares UTHR – United Therapeutics Corporation Stock Price stock today
news today UTHR – United Therapeutics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch UTHR – United Therapeutics Corporation yahoo finance google finance
stock history UTHR – United Therapeutics Corporation invest stock market
stock prices UTHR premarket after hours
ticker UTHR fair value insiders trading